July 30 (Reuters) – Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million to expand pharmaceutical manufacturing capacity in the U.S. and strengthen the domestic medicine supply chain, Resilience said on Thursday.
Global drugmakers have been ramping up U.S. manufacturing since last year and stockpiling inventory as President Donald Trump’s administration moves to impose 100% tariffs on branded drugs unless companies cut prices or make medicines domestically.
• Resilience said the investment will increase the production of critical medicines and create 400 new high-skilled jobs in the Cincinnati, Ohio region.
• The company’s manufacturing operations in the region will now include Lilly’s KwikPen injectable device for treating diabetes and obesity, it added.
• The multi-year manufacturing partnership between Lilly and Resilience, which began in 2023, has already produced more than 150 million doses of medicines for U.S. patients in vial and pre-filled syringe formats, according to Resilience.
• Lilly’s manufacturing head Edgardo Hernandez said the partnership reflects the drugmaker’s efforts to meet rising demand for its medicines.
• Lilly’s U.S. capital expansion commitments since 2020 total more than $55 billion and it plans to break ground on several of its recently announced U.S. manufacturing sites this year.
(Reporting by Christy Santhosh in Bengaluru; Editing by Jonathan Ananda)
